Providing Enhanced Medical Support for Patients with Primary Immunodeficiency Disorders (PIDD): A Patient-Guided Intervention to Ensure Patient Engagement During a Global Pandemic and Beyond

In 2021, the American Academy of Allergy, Asthma and Immunology (AAAAI), the AXDEV Group, and the Immune Deficiency Foundation (IDF) conducted a survey of over 300 PIDD patients. The purpose of this survey was to identify, from a patient perspective, the knowledge and practice gaps that have existed among the healthcare providers (HCPs) they have seen regarding PIDD. The findings indicated a need to address HCPs’ skills and confidence in recognizing signs and symptoms of PIDD, the use and interpretation of diagnostic tests, how to engage patients in essential health discussions, and maintaining optimal patient care via telehealth. View a summary of the results here.

To address these gaps in knowledge and practice, the AAAAI has developed this program, which contains three impactful online modules that cover symptoms, telehealth, and diagnosis. Each module includes information about best practices for communicating with patients and links to patient and practitioner resources. Learners will complete a pre-test before completing the modules and an assessment within each of the three modules. CME credit is available for each module in the program.

This course has also been approved to meet the quality improvement requirement of the American Board of Allergy and Immunology's (ABAI) Maintenance of Certification program. To meet the MOC requirement:

Complete the "Measure Your Existing Knowledge", "Signs and Symptoms of PIDD", and "Beyond the Doctor's Office: Telehealth for PIDD Patient Care" modules.
Complete at least one of the two diagnostic modules ("A Practical Patient Care Scenario for Primary Care Providers" or "A Practical Patient Care Scenario for Allergy/Immunology Specialists").
Complete the "MOC Follow-Up Assessment" module. This module requires that at least 30 days have passed since completing the previous modules in the course, so a link will be emailed to you.

After these steps have been successfully completed, the ABAI will be notified that you have met the MOC requirement.

Providing Enhanced Medical Support for Patients with PIDD is funded through an educational grant from Pfizer.

Target Audience

Allergist/Immunologists
Primary Care Providers
Fellows-in-Training
Nurses and Nurse Practitioners
Physician Assistants and Other Allied Health Professionals

Learning Objectives

Upon completion of this activity, participants should be able to:

Reduce the period of time and the number of patient cases that involve an extended period of uncertainty without a clear diagnosis of PIDD
Recognize those patient scenarios that would benefit from a specialist’s involvement in the process of diagnosis and/or treatment
Utilize available tools and strategies for recognizing, treating, and maintaining the optimal health of patients with PIDD
Confidently implement new knowledge, strategies, and/or techniques related to PIDD that align with quality of patient care

AAAAI Logo Logo for AxDev Logo for Immune Deficiency Foundation

Summary

Available credit:

2.00 Attendance
Attendance credit.
2.00 CE
CE credit.
2.00 CME
CME credit.

Course opens:

08/01/2023

Course expires:

07/31/2025

Cost:

$0.00

Rating:

Steering Committee

Autry Beamon
Relevant Relationships: None

John Boyle
Relevant Relationships: None

Victoria Dimitriades, MD FAAAAI
University of California, Davis Medical Center, Sacramento, CA
Relevant Relationships: None

Carla Duff, CPNP-PC APRN MSN CCR
University of South Florida, St. Petersburg, FL
Relevant Relationships: CSL Behring LLC, Takeda, Grifols: Consultant

Katja Fort Rhoden
Relevant Relationships: None

Jennifer W. Leiding, MD FAAAAI
University of South Florida, St. Petersburg, FL
Relevant Relationships: Pharming: Consultant; Horizon Pharma: Grant; CSL-Behring, Horizon Therapeutics: Speaker; CSL-Behring, Horizon Therapeutics, Orchard Theraputics: Advisory Board

Kenneth Paris, MD MPH FAAAAI
Louisiana State University Health Sciences Center, New Orleans, LA
Relevant Relationships: Biocryst, GSK, Takeda: Advisory Board; Takeda: Speaker

Nicholas Rider, DO FAAAAI
Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Relevant Relationships: UpToDate: Consultant; CSL Behring, Horizon Therapeutics, Takeda, Pharming Helathcare: Advisory Board

Christopher Scalchunes
Immune Deficiency Foundation (IDF), Towson, MA
Relevant Relationships: None

Kathleen Sullivan, MD PhD FAAAAI
Children's Hospital of Philadelphia, Philadelphia, PA
Relevant Relationships: Immune Deficiency Foundation, Enzyvant: Consultant; Elsevier, UpToDate: Royalty; Department of Defense, Lupus Foundation of America: Research Grant

M. Elizabeth Younger, CRNP PhD
Johns Hopkins School of Medicine, Baltimore, MD
Relevant Relationships: CSL Behring (Immunoglobulin): Consultant; HorizonPharma (Chronic Grnulomatous Disease), Grifols (Primary immunodeficiency): Speaker

Elizabeth Hoffman, MA MS
American Academy of Allergy, Asthma and Immunology, Milwaukee, WI
Relevant Relationships: None

Ellen Price, MA MSEd
American Academy of Allergy, Asthma and Immunology, Milwaukee, WI
Relevant Relationships: None

Monica Augustyniak, MPH
AXDEV Group, Brossard, Québec
Relevant Relationships: None

Ginny Jacobs, MEd MLS
AXDEV Global, Virginia Beach, Virginia
Relevant Relationships: None

Pam McFadden
AXDEV Global, Virginia Beach, Virginia
Relevant Relationships: None

Case Presenters

Sasha Alvarado
Allergy, Asthma & Immunology Center, Murphy, TX
Relevant Relationships: None

Nicholas Hartog
Spectrum Health, Rockford, MI
Relevant Relationships:

Edith Schussler
Weill Cornell Medicine, New York, NY
Relevant Relationships: None

Jennifer Yonkof
ProMedica Physicians Group, Perrysburg, OH
Relevant Relationships: None

Content Review

Stuart Abramson, MD PhD FAAAAI
Shannon Medical Center/Shannon Clinic, San Angelo, TX
Relevant Relationships: None

Kevin Parks, MD FAAAAI
AAC/CRI of Southern Oregon, P.C., Medford, OR
Relevant Relationships: None

The information disclosed by the case presenters and steering committee members was reviewed in accordance with the AAAAI Disclosure Policy. All potential conflicts of interest were mitigated by the planners, faculty, and reviewers prior to their participation in the development of this activity.

AAAAI DISCLOSURE POLICY

Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma & Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of certain information from faculty members of educational activities designated for CME credit by the AAAAI. Prior to the activity, authors and reviewers are required to disclose all relationships that meet the following parameters

Employment: Name of employer and job title.
Financial interests: All organizations, other than the employer, from which the faculty member or a member of his/her immediate family or household receives annual remuneration in any amount (including grants, honoraria and consulting fees).
Research interests: All organizations which support research projects for which the faculty member or member of his/her immediate family or household serves as an investigator.
Legal Consultation Services/Expert Witness Testimony: All topics on which the faculty member provided legal consultation and/or expert witness testimony during the previous calendar year.
Organizational interests: All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.
Gifts: All organizations from which the faculty member or a member of his/her immediate family or household have received a gift of any amount in the last year.
Other interests: All interests of the faculty member or a member of his/her immediate family or household that would be judged by a majority of his/her peers to be more than casual and/or likely to impact his/her ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.

Accreditation Statement

The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The American Academy of Allergy, Asthma & Immunology designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABMS MOC Approval Statement

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, Providing Enhanced Medical Support for Patients with Primary Immunodeficiency Disorders has met the requirements as a MOC Part IV Performance Improvement CME and MOC Part II Self-Assessment and/or CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part IV Performance Improvement CME
Allergy and Immunology

ABMS MOC Part II CME Activity
Family Medicine

https://www.continuingcertification.org/activity/providing-enhanced-medical-support-for-patients-with-primary-immunodeficiency-disorders-pidd-a-patient-guided-intervention-to-ensure-patient-engagement-during-a-global-pandemic-and-beyond/

CE Designation Statement

The American Academy of Allergy, Asthma, & Immunology (AAAAI) is a Provider, approved by the California Board of Registered Nursing, Provider #10704, for up to 2.00 Contact Hours.

AAAAI Privacy Policy

To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at cme@aaaai.org.

Questions

Registration and credit claiming questions should be directed to cme@aaaai.org.

Available Credit

2.00 Attendance
Attendance credit.
2.00 CE
CE credit.
2.00 CME
CME credit.

Status

Price

Activity Title

Locked

$0.00Included

Providing Enhanced Medical Support for Patients with Primary Immunodeficiency Disorders (PIDD): A Patient-Guided Intervention to Ensure Patient Engagement During a Global Pandemic and Beyond